Can Chemo-Induced Pain Be Cured?

Chemotherapy induced neuropathic (CINP) can be reduced by blocking the expression of TRPV1 receptor through a small interfering RNA molecule (siRNA).

Chemotherapy induced neuropathic (CINP) can be cured by genetically manipulated and delivered siRNA to target sites by nanotechnology, reveals a new research conducted by a team of the Institute of Medical Sciences and IIT, Banaras Hindu University (BHU).//

The research was conducted by Dr. Nimisha Verma of the department of anesthesiology, IMS-BHU and Dr. Vinod Tiwari of the department of pharmaceutical engineering, IIT(BHU).

World Cancer Day: Fear of Chemotherapy Delays Breast Cancer Diagnosis
Poor lifestyle changes are a known cause of the rising number of breast cancers. Let's create awareness and prevent breast cancer with early diagnosis and treatment.

‘Blocking the expression of TRPV1 receptor through a small interfering RNA molecule (siRNA) can help reduce the chemotherapy-induced neuropathic (CINP) in cancer patients.’

This study has been published in January 2022 edition of a globally reputed Life Science Journal.

Dr. Tiwari said that the cancer patients suffer from severe pain. Not only the disease, but the treatment of cancer can also cause unbearable pain.

One such type of pain is chemotherapy-induced neuropathic pain (CINP), which is among the most common clinical complications associated with the use of anti-cancer drugs. It is a significant dose-limiting and treatment-limiting side effect of treatment.

Nanotechnology Improves Delivery of Chemotherapy, Says Study
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

The CINP occurs in nearly 68.1 percent of the cancer patients receiving chemotherapeutic drugs.

The therapeutic glory of TRPV1 is well recognized in clinics which give a promising insight into the treatment of pain.

Chemotherapy Fails for Few Patients Due to Mutations: Study
Mutations in a crucial gene are the key reason that chemotherapy fails in some patients with blood cancer.

According to him, the adverse effects associated with some of the antagonists directed the scientists towards RNA interference (RNAi), a tool to silence gene expression.

TRPV1 is widely present in the nerve cells and it has been reported that the higher expression of TRPV1 plays a critical role in chemotherapy-induced pain.

Half The Dose of Chemo Prevents Testicular Cancer: 111 trial
New trial showed that giving men one cycle of chemotherapy was as effective at preventing men's testicular cancer from coming back as the two cycles used as standard.

This unrelenting pain responds poorly to common analgesics and even opioids. The available treatment for CINP has some severe side effects.

This was the triggering question when scientists ventured into research on TRPV1 siRNA formulation.

For this, Dr. Nimisha Verma and Dr. Vinod Tiwari came up with a novel solution to this problem through genetic engineering and nanotechnology.

According to them, the research involves the blocking of expression of TRPV1 receptor through a small interfering RNA molecule (siRNA).

The novel siRNA formulation suggested by the ongoing research has shown quick management of pain without side-effects which would be very effective for the patients.

Source-IANS